Diabetic Eye Disease
暂无分享,去创建一个
[1] P. Mitchell,et al. Visual acuity and the causes of visual loss in Australia. The Blue Mountains Eye Study. , 1996, Ophthalmology.
[2] Hiroshi Yamamoto,et al. Inhibition of diabetic leukostasis and blood-retinal barrier breakdown with a soluble form of a receptor for advanced glycation end products. , 2007, Investigative ophthalmology & visual science.
[3] P. Oates,et al. Aldose reductase, ocular diabetic complications and the development of topical Kinostat® , 2016, Progress in Retinal and Eye Research.
[4] J. Baynes,et al. N-epsilon-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. , 1997, The Biochemical journal.
[5] Jin Hyoung Kim,et al. RAGE mediated intracellular Aβ uptake contributes to the breakdown of tight junction in retinal pigment epithelium , 2015, Oncotarget.
[6] A. Saxena,et al. Advanced glycation end products and diabetic retinopathy , 2012, Journal of ocular biology, diseases, and informatics.
[7] N. Lois,et al. Diabetic-like corneal sensitivity loss in galactose-fed rats ameliorated with aldose reductase inhibitors. , 1998, Journal of ocular pharmacology and therapeutics : the official journal of the Association for Ocular Pharmacology and Therapeutics.
[8] T. Chikama,et al. Efficacy of substance P and insulin-like growth factor-1 peptides for preventing postsurgical superficial punctate keratopathy in diabetic patients , 2009, Japanese Journal of Ophthalmology.
[9] A. Schmidt,et al. The RAGE axis in early diabetic retinopathy. , 2005, Investigative ophthalmology & visual science.
[10] S. Genuth,et al. Glucosepane: a poorly understood advanced glycation end product of growing importance for diabetes and its complications , 2014, Clinical chemistry and laboratory medicine.
[11] U. F. Ezepue. Magnitude and causes of blindness and low vision in Anambra State of Nigeria (results of 1992 point prevalence survey). , 1997, Public health.
[12] R. Cumming,et al. Prevalence of cataract in Australia: the Blue Mountains eye study. , 1997, Ophthalmology.
[13] Masaru Miyagi,et al. Drusen proteome analysis: An approach to the etiology of age-related macular degeneration , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[14] D L DeMets,et al. The Wisconsin epidemiologic study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. , 1984, Archives of ophthalmology.
[15] M. Araie,et al. Advanced glycation end products in diabetic corneas. , 2000, Investigative ophthalmology & visual science.
[16] A. Milam,et al. Receptor for advanced glycation end products and age-related macular degeneration. , 2004, Investigative ophthalmology & visual science.
[17] B. Munoz,et al. Diabetes and diabetic retinopathy in a Mexican-American population: Proyecto VER. , 2001, Diabetes care.
[18] M. C. Leske,et al. Prevalence of lens opacities in the Barbados Eye Study. , 1997, Archives of ophthalmology.
[19] V. Monnier,et al. Nonenzymatic browning in vivo: possible process for aging of long-lived proteins. , 1981, Science.
[20] S. Horiuchi,et al. Advanced glycation end products in age-related macular degeneration. , 1998, Archives of ophthalmology.
[21] G. Rubin,et al. Causes of blindness and visual impairment in a population of older Americans: The Salisbury Eye Evaluation Study. , 2000, Archives of ophthalmology.
[22] J. Glenn,et al. The role of advanced glycation end products in retinal ageing and disease. , 2009, Biochimica et biophysica acta.
[23] D. DeMets,et al. The Wisconsin epidemiologic study of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. , 1984, Archives of ophthalmology.
[24] R. Klein,et al. The relation of socioeconomic factors to age-related cataract, maculopathy, and impaired vision. The Beaver Dam Eye Study. , 1994, Ophthalmology.
[25] T. Lyons,et al. The Maillard reaction in vivo , 1991, Zeitschrift für Ernährungswissenschaft.
[26] T. Chikama,et al. Promotion of corneal epithelial wound healing in diabetic rats by the combination of a substance P-derived peptide (FGLM-NH2) and insulin-like growth factor-1 , 2003, Diabetologia.
[27] Yuichi Kaji,et al. The role of advanced glycation end products in retinal microvascular leukostasis. , 2003, Investigative ophthalmology & visual science.
[28] Y. Tano,et al. Aldose reductase inhibitor (CT-112) eyedrops for diabetic corneal epitheliopathy. , 1988, American journal of ophthalmology.